Barry Greene
Barry Greene, appointed CEO of Sage Therapeutics, is praised for building sustainable, inclusive, and successful team cultures, with peers confident in his leadership for commercialization.
Greene's extensive experience at Alnylam, where he built the salesforce and established key partnerships, positions him well to lead Sage's transition from biotech to a profitable company.
Greene's strategy for Sage includes expanding opportunities, navigating trial outcomes, and maximizing reimbursement rates, with a focus on high-potential drugs like Zuranolone and SAGE-718.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.